Hisamitsu Pharmaceut (HTSUF) 36.2500 $HTSUF Restless

New Post Public Reply Private Reply Replies (0) Message Board

Oct 11, 2015 at 10:07 AM

Hisamitsu Pharmaceut (HTSUF) 36.2500 $HTSUF

Restless Legs Syndrome Pipeline Review, H2 2015 - 8 Companies & 8 Drug Profiles
M2 - Tue Sep 22, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m55jdp/restless_legs) has announced the addition of the "Restless Legs Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Restless Legs Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restless Legs Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexza Pharmaceuticals, Inc. - Ascendis Pharma A/S - Hisamitsu Pharmaceutical Co., Inc. - Ligand Pharmaceuticals, Inc. - Mundipharma International Ltd - Omeros Corporation - Serina Therapeutics, Inc. - Vifor Pharma AG Drug Profiles - (naloxone hydrochloride oxycodone hydrochloride) ER - aplindore fumarate - AZ-008 - ferric carboxymaltose - OMS-527 - pramipexole dihydrochloride - ropinirole hydrochloride - SER-214 For more information visit http://www.researchandmarkets.com/research/m5...tless_legs
ASND: 17.24 (+0.05), ALXA: 1.24 (-0.02), OMER: 12.66 (+0.58)

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015 - 30 Companies & 52 Drug Profiles
M2 - Fri Jul 31, 9:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/57stt9/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alcobra Ltd - Amarantus Bioscience Holdings, Inc. - Arbor Pharmaceuticals, LLC. - Cerecor Inc. - Collegium Pharmaceutical, Inc. - Curemark, LLC - DURECT Corporation - Eli Lilly and Company - H. Lundbeck A/S - Hisamitsu Pharmaceutical Co., Inc. - Integrative Research Laboratories Sweden AB - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Merck & Co., Inc. - Mnemosyne Pharmaceuticals, Inc. - Neos Therapeutics, Inc. - NeuroDerm Ltd. - Otsuka Holdings Co., Ltd. - P2D Bioscience - Polleo Pharma Limited - Reviva Pharmaceuticals Inc. - Samyang Biopharmaceuticals Corporation - Shire Plc - Signature Therapeutics, Inc - Sunovion Pharmaceuticals Inc. - Supernus Pharmaceuticals, Inc. - Taisho Pharmaceutical Co., Ltd. - Takeda Pharmaceutical Company Limited - Tris Pharma, Inc. - Vernalis Plc For more information visit http://www.researchandmarkets.com/research/57...on_deficit
KMPH: 18.83 (-0.18), ADHD: 5.66 (+0.17), SUPN: 14.48 (+0.16), COLL: 20.67 (-0.19), LLY: 86.14 (+2.37), DRRX: 2.13 (+0.02), NEOS: 18.69 (-0.57), NDRM: 22.56 (-0.09), SHPG: 200.90 (-1.85), MRK: 50.95 (-0.07), ITCI: 43.85 (+1.72)

Restless Legs Syndrome Therapeutics Pipeline Review 2015 - 7 Companies & 7 Drug Profiles
M2 - Wed Mar 11, 7:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mqjzpr/restless_legs) has announced the addition of the "Restless Legs Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Restless Legs Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restless Legs Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexza Pharmaceuticals, Inc. - Ascendis Pharma A/S - Hisamitsu Pharmaceutical Co., Inc. - Ligand Pharmaceuticals, Inc. - Omeros Corporation - Purdue Pharma L.P. - Serina Therapeutics, Inc. Drug Profiles - (naloxone hydrochloride oxycodone hydrochloride) ER - ACP-006 - aplindore fumarate - AZ-008 - OMS-527 - ropinirole hydrochloride - SER-214 For more information visit http://www.researchandmarkets.com/research/mq...tless_legs
ASND: 17.24 (+0.05), ALXA: 1.24 (-0.02), OMER: 12.66 (+0.58)

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Pipeline Review, H2 2014 - 27 Companies & 49 Drug Profiles
M2 - Mon Nov 03, 8:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/3gdhmp/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - DURECT Corporation - Eli Lilly and Company - Taisho Pharmaceutical Co., Ltd. - NeuroDerm Ltd. - Takeda Pharmaceutical Company Limited - Richter Gedeon Nyrt. - Pfizer Inc. - Purdue Pharma L.P. - Shire Plc - Vernalis plc - Collegium Pharmaceutical, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Arbor Pharmaceuticals, LLC. - Curemark, LLC - Supernus Pharmaceuticals, Inc. - Intra-Cellular Therapies, Inc. - Tris Pharma, Inc. - Neos Therapeutics, Inc. - KemPharm, Inc. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - Alcobra Ltd - Sunovion Pharmaceuticals Inc. - Signature Therapeutics, Inc - P2D Bioscience For more information visit http://www.researchandmarkets.com/research/3g...on_deficit
ADHD: 5.66 (+0.17), PFE: 33.24 (+0.15), SUPN: 14.48 (+0.16), LLY: 86.14 (+2.37), DRRX: 2.13 (+0.02), NDRM: 22.56 (-0.09), SHPG: 200.90 (-1.85), ITCI: 43.85 (+1.72)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

U.S. Gold Corp. Gears Up for Key October Event

Marking Calendars for the Emerging Growth Showdown There's nothing quite like the buzz leading up to an event where you know someone’s either gonna make a splash or barely leave a ripple. U.S. Gold Corp. is drawing some attention ahead of the Emerging Growth Conference on October 29, 2026. This ain't just any corporate dog-and-pony show—it's a chance for the Gold...

Firmable Climbs G2 Ranks in Sales Intelligence

Success stories aren't written overnight, and Firmable's recent leap in G2's rankings proves that point. This AI-native B2B sales powerhouse has muscled its way from #8 to #4 on the global Momentum Grid for Sales Intelligence, marking a dramatic rise that's hard to ignore. Being recognized at this level shows the company's on a solid path, but let's see what makes this...

North Island Credit Union Eases Student Access to Banking

Breaking Down Barriers with Student Banking Services Stumble into any financial setup these days, and you'll hear the same refrain: young people need more access to banking. North Island Credit Union seems to have taken that idea to heart, landing a national Bank On certification for their Student Checking account. It ain't just any badge; it's the mark of reliability,...

Gargle App Elevates Dental Marketing Transparency, ROI Focus

Dentists Finally See the Whole Picture with Gargle's App Out in Lehi, Utah, there's a little tech shakeup courtesy of Gargle—a name some might squint at if they haven't been following dental-focused digital marketing. Now, with their latest move, the Gargle App, we're talking about pulling back the curtain and giving dental practices a clear view of their marketing...

Enertech's New Moves Aim to Make Geothermal Mainstream

Breaking Through Financial Barriers in Geothermal Energy Finally, we're seeing some real movement in the geothermal heat pump sector. The longtime hurdles that kept ground-sourced heating and cooling tech at arm's length from the everyday homeowner are starting to tumble, thanks to Enertech Global's latest initiatives. Enertech's Double Deal: A New Lease on Geothermal...

Northeast Indiana Bancorp Shows Solid Third Quarter Gains

Holding Steady in a Shaky Market In a market often rocked by turbulence, it seems Northeast Indiana Bancorp, Inc. has found a decent footing to stand on. Announcing their third-quarter results for 2026, they’ve posted net income of $1.991 million, showcasing a neat jump from the $1.793 million in the same period last year. Not bad at all for the parent company of First...

Valmet's Strategic Moves and Financial Gains Explained

Valmet's Strategic Playbook for Growth Anyone keeping tabs on Valmet's recent parade of press releases knows they're on a darn aggressive growth spurt. Talk about shaking things up with a firm grip on the paper and forest products sector and beyond. Their interim review from January to September 2026 spells it out with strong orders received and a solid increase in...

New Research Awards Target Drug Resistance in Cancers

Well, this is a breath of fresh air in the lung cancer scene, let's talk about some promising news for those battling RET-positive cancers. The LUNGevity Foundation and RETpositive have handed out some well-deserved awards to researchers aiming to crack the stubborn nut of drug resistance in RET-positive cancer therapies. Changing the Game for RET-positive Cancer RET gene...

Technical Deep Dive into HONOR X9e Pro's Durability

Rethinking Smartphone Power HONOR's latest device, the X9e Pro, flaunts an 11,000mAh battery—stuck it right behind a neat cover without making the thing feel like a brick. You'd think with a battery that big, they’d have to hire bodybuilders to lift it, but nope. At 8.08mm thick and weighing just 203g, this phone bucks the bulk. They’ve squeezed the power of a power...

MetroScape: Local Roots Fuel Bold DFW Growth Plans

A Local Business with Big Aspirations Here's the deal, folks: Local guys Dr. Marc Nickell and Chris Brewer snatched up MetroScape Landscape like it was the last slice of grandma's pie. Why? Not just for the greenbacks—they're putting down roots in their very own backyard, the Dallas-Fort Worth area. What Does Local Really Mean? Look, it's one thing hitting up a...